Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study
Abstract Background Sarcopenia and obesity are two abnormal body composition phenotypes, and sarcopenic obesity (SO) is characterized by both low skeletal muscle mass (sarcopenia) and high adiposity (obesity). SO negatively influences the clinical status of patients with chronic obstructive pulmonar...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-023-02702-2 |
| _version_ | 1827724942105378816 |
|---|---|
| author | Zilin Wang Xiaoming Zhou Mingming Deng Yan Yin Yanxia Li Qin Zhang Yiding Bian Jinrui Miao Jiaye Li Gang Hou |
| author_facet | Zilin Wang Xiaoming Zhou Mingming Deng Yan Yin Yanxia Li Qin Zhang Yiding Bian Jinrui Miao Jiaye Li Gang Hou |
| author_sort | Zilin Wang |
| collection | DOAJ |
| description | Abstract Background Sarcopenia and obesity are two abnormal body composition phenotypes, and sarcopenic obesity (SO) is characterized by both low skeletal muscle mass (sarcopenia) and high adiposity (obesity). SO negatively influences the clinical status of patients with chronic obstructive pulmonary disease (COPD). However, the studies exploring the prevalence and clinical effects of SO in COPD patients are limited. Our study aimed to elucidate the prevalence and impact of SO on COPD patients. Methods In this cross-sectional study, the pulmonary function, St. George’s Respiratory Questionnaire, exercise tolerance, body composition, and serum levels of resistin and TNF-α were assessed in 198 COPD patients. The clinical value of serum resistin and TNF-α for predicting SO in patients with COPD was evaluated. Results In the 198 patients with COPD, the prevalence rates of sarcopenia, obesity, and SO in COPD patients were 27.27%, 29.8%, and 9.6%, respectively. Patients with SO experienced more severe symptoms of dyspnea and worse health related quality of life. The expression of resistin increased in patients with SO compared to other patients. The AUC value of serum resistin level for predicting SO was 0.870 (95% CI: 0.799–0.940). BMI (OR: 1.474, 95% CI: 1.124–1.934) and resistin (OR: 1.001, 95% CI: 1.000-1.002) levels were independent risk factors of SO in patients with COPD in Multivariate analysis. Conclusion The prevalence rates of SO in COPD patients was 9.6%. COPD accompanied by SO is significantly associated with worse pulmonary function and poor physical performance. Serum resistin may be a potential adjunct for predicting SO in COPD patients. |
| first_indexed | 2024-03-10T22:22:33Z |
| format | Article |
| id | doaj.art-bd8618478dfd4c3dbf6c0c68a8057f73 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-03-10T22:22:33Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-bd8618478dfd4c3dbf6c0c68a8057f732023-11-19T12:14:26ZengBMCBMC Pulmonary Medicine1471-24662023-10-012311810.1186/s12890-023-02702-2Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional studyZilin Wang0Xiaoming Zhou1Mingming Deng2Yan Yin3Yanxia Li4Qin Zhang5Yiding Bian6Jinrui Miao7Jiaye Li8Gang Hou9National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship HospitalDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College, Fuwai Hospital, Chinese Academy of Medical SciencesNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship HospitalDepartment of Pulmonary and Critical Care Medicine, First Hospital of China Medical UniversityRespiratory Department, The First Affiliated Hospital of Dalian Medical UniversityNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship HospitalNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship HospitalNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship HospitalNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship HospitalNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship HospitalAbstract Background Sarcopenia and obesity are two abnormal body composition phenotypes, and sarcopenic obesity (SO) is characterized by both low skeletal muscle mass (sarcopenia) and high adiposity (obesity). SO negatively influences the clinical status of patients with chronic obstructive pulmonary disease (COPD). However, the studies exploring the prevalence and clinical effects of SO in COPD patients are limited. Our study aimed to elucidate the prevalence and impact of SO on COPD patients. Methods In this cross-sectional study, the pulmonary function, St. George’s Respiratory Questionnaire, exercise tolerance, body composition, and serum levels of resistin and TNF-α were assessed in 198 COPD patients. The clinical value of serum resistin and TNF-α for predicting SO in patients with COPD was evaluated. Results In the 198 patients with COPD, the prevalence rates of sarcopenia, obesity, and SO in COPD patients were 27.27%, 29.8%, and 9.6%, respectively. Patients with SO experienced more severe symptoms of dyspnea and worse health related quality of life. The expression of resistin increased in patients with SO compared to other patients. The AUC value of serum resistin level for predicting SO was 0.870 (95% CI: 0.799–0.940). BMI (OR: 1.474, 95% CI: 1.124–1.934) and resistin (OR: 1.001, 95% CI: 1.000-1.002) levels were independent risk factors of SO in patients with COPD in Multivariate analysis. Conclusion The prevalence rates of SO in COPD patients was 9.6%. COPD accompanied by SO is significantly associated with worse pulmonary function and poor physical performance. Serum resistin may be a potential adjunct for predicting SO in COPD patients.https://doi.org/10.1186/s12890-023-02702-2COPDSarcopenic obesitySarcopeniaResistin |
| spellingShingle | Zilin Wang Xiaoming Zhou Mingming Deng Yan Yin Yanxia Li Qin Zhang Yiding Bian Jinrui Miao Jiaye Li Gang Hou Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study BMC Pulmonary Medicine COPD Sarcopenic obesity Sarcopenia Resistin |
| title | Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study |
| title_full | Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study |
| title_fullStr | Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study |
| title_full_unstemmed | Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study |
| title_short | Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study |
| title_sort | clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease a cross sectional study |
| topic | COPD Sarcopenic obesity Sarcopenia Resistin |
| url | https://doi.org/10.1186/s12890-023-02702-2 |
| work_keys_str_mv | AT zilinwang clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT xiaomingzhou clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT mingmingdeng clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT yanyin clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT yanxiali clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT qinzhang clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT yidingbian clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT jinruimiao clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT jiayeli clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy AT ganghou clinicalimpactsofsarcopenicobesityonchronicobstructivepulmonarydiseaseacrosssectionalstudy |